Aortitis in giant cell arteritis : Diagnosis, prognosis and treatment
Copyright © 2019 Elsevier Masson SAS. All rights reserved..
Aortitis, defined by aortic parietal thickening, is noted in about 50% of patients with giant cell arteritis (GCA). Aortic structural lesions, ectasia or aneurism, may occur with or without inflammatory aspect of the aorta, sometimes since the diagnosis of GCA, but more frequently during follow-up. Assessment of aortic involvement, which has to be searched in each patient at the diagnosis of GCA, can be assessed using aortic imaging, angio-CT, angio-MRI or PET-CT. Prognosis of aortitis and its complications remains poorly known, but mortality due to serious events like aneurism rupture or aortic dissection, could be potentially reduced with precocious diagnosis and regular monitoring. Treatment of GCA-related aortitis is based on high-dose glucosteroids, with an initial prednisone dose at 0.7 mg/kg/d, as recommended by the French Study Group for large vessel vasculitis (GEFA). Aortic ectasia and aneurisms have to be monitored, in order to propose aortic surgery in the best conditions as possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Presse medicale (Paris, France : 1983) - 48(2019), 9 vom: 01. Sept., Seite 956-967 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Aortite de l’artérite à cellules géantes : diagnostic, pronostic et traitement |
|---|
| Beteiligte Personen: |
Enfrein, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 17.10.2019 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lpm.2019.04.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299399559 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299399559 | ||
| 003 | DE-627 | ||
| 005 | 20231225100240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.lpm.2019.04.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM299399559 | ||
| 035 | |a (NLM)31327542 | ||
| 035 | |a (PII)S0755-4982(19)30282-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Enfrein, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aortitis in giant cell arteritis |b Diagnosis, prognosis and treatment |
| 246 | 3 | 3 | |a Aortite de l’artérite à cellules géantes : diagnostic, pronostic et traitement |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.10.2019 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Aortitis, defined by aortic parietal thickening, is noted in about 50% of patients with giant cell arteritis (GCA). Aortic structural lesions, ectasia or aneurism, may occur with or without inflammatory aspect of the aorta, sometimes since the diagnosis of GCA, but more frequently during follow-up. Assessment of aortic involvement, which has to be searched in each patient at the diagnosis of GCA, can be assessed using aortic imaging, angio-CT, angio-MRI or PET-CT. Prognosis of aortitis and its complications remains poorly known, but mortality due to serious events like aneurism rupture or aortic dissection, could be potentially reduced with precocious diagnosis and regular monitoring. Treatment of GCA-related aortitis is based on high-dose glucosteroids, with an initial prednisone dose at 0.7 mg/kg/d, as recommended by the French Study Group for large vessel vasculitis (GEFA). Aortic ectasia and aneurisms have to be monitored, in order to propose aortic surgery in the best conditions as possible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Espitia, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnard, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Agard, Christian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Presse medicale (Paris, France : 1983) |d 1986 |g 48(2019), 9 vom: 01. Sept., Seite 956-967 |w (DE-627)NLM012618160 |x 2213-0276 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2019 |g number:9 |g day:01 |g month:09 |g pages:956-967 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lpm.2019.04.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2019 |e 9 |b 01 |c 09 |h 956-967 | ||